Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Total Current Liabilities: 2019-2024

Historic Total Current Liabilities for Revolution Medicines (RVMD) over the last 6 years, with Dec 2024 value amounting to $163.9 million.

  • Revolution Medicines' Total Current Liabilities rose 121.55% to $245.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.6 million, marking a year-over-year increase of 121.55%. This contributed to the annual value of $163.9 million for FY2024, which is 13.95% up from last year.
  • Revolution Medicines' Total Current Liabilities amounted to $163.9 million in FY2024, which was up 13.95% from $143.9 million recorded in FY2023.
  • Revolution Medicines' 5-year Total Current Liabilities high stood at $163.9 million for FY2024, and its period low was $47.2 million during FY2020.
  • For the 3-year period, Revolution Medicines' Total Current Liabilities averaged around $123.2 million, with its median value being $143.9 million (2023).
  • Data for Revolution Medicines' Total Current Liabilities shows a peak YoY surged of 132.08% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Revolution Medicines' Total Current Liabilities stood at $47.2 million in 2020, then grew by 27.93% to $60.4 million in 2021, then increased by 2.71% to $62.0 million in 2022, then soared by 132.08% to $143.9 million in 2023, then rose by 13.95% to $163.9 million in 2024.